Retrophin Reports Second Quarter 2020 Financial Results
July 30, 2020 16:01 ET
|
Retrophin, Inc.
Enrollment ahead of schedule in Phase 3 PROTECT Study of sparsentan in IgAN; topline proteinuria data from both pivotal studies in FSGS and IgAN now anticipated in 2021 Net product sales increased...